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Abstract
Background: Anti-malarial resistance in Plasmodium falciparum remains an obstacle for malaria control.
Resistance-associated genes were analysed in Brazilian samples over four decades to evaluate the impact of different
treatment regimens on the parasite genetic profile.
Methods: Samples were collected on filter paper from patients infected in the Amazon region from 1984 to 2011.
DNA was extracted with Chelex® 100 and monoinfection confirmed by PCR. SNPs in the pfcrt, pfmdr1, pfdhfr and pfdhps
genes were assessed by PCR-RFLP. The pfmdr1 copy number was estimated using real time quantitative PCR with SYBR®
Green. Parasite response was assessed ex vivo with seven concentrations of each anti-malarial. Patients were treated
according to Brazilian guidelines: quinine plus tetracycline or mefloquine in period 1 and ACT in period 2.
Results: All 96 samples presented the pfcrt 76T mutant throughout the assessed periods. In addition, all isolates
showed ex vivo chloroquine resistance. The pfmdr1 86Y was detected in 1.5% of samples in period 1, and in 25% in
period 2. All samples presented the pfmdr1 1246Y. The analysis of pfmdr1 copy number showed amplification in 37.3%
in period 1 and in 42% in period 2. Mutations in pfdhfr were shown as follows: 51I in all samples in period 1 and in
81.2% in period 2; 59R in 6.4% in period 2. The pfdhfr 108N and the pfdhps 437G were seen in all samples along time;
the pfdhps 540E in 93.7% in period 1 and in 75% in period 2.
Conclusions: The 76T mutation associated to chloroquine resistance is still present in the parasite population,
although this anti-malarial was withdrawn from the chemotherapy of P. falciparum in Brazil in the mid-1980s. All isolates
assayed ex vivo for chloroquine showed resistant phenotype and 76T. No association was observed between pfmdr1
mutations and resistance to quinine, mefloquine and artemisinin derivatives. Additionally, the pfdhfr 108N mutation
was detected in all samples throughout the evaluated periods, demonstrating fixation of the mutant allele in the
parasite population. Changes in Brazilian national guidelines for the malaria chemotherapy in the last 27 years yielded
a discreet genetic impact in the parasite population.
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Background
Malaria remains a major public health concern, with
the occurrence of about 207 million cases and ac-
counting for 627,000 deaths worldwide in 2012 [1].
In Brazil 177,767 malaria cases were reported in
2013, 99.6% of which were acquired in the Amazon
region, the main endemic area for the disease in
South America. In terms of species distribution,
Plasmodium vivax accounted for 82% of Brazilian
malaria cases, followed by Plasmodium falciparum
(16.5%) and mixed infections (1.5%) [2]. Previously,
there has been higher prevalence of P. falciparum
[1]. However, P. falciparum is known to cause most
complicated clinical cases and to have become resistant to
almost all anti-malarial drugs.
Chloroquine-resistant P. falciparum was initially reported
in Brazil in the 1960s [3] and thereafter in other South
American countries [4]. Further similar cases were reported
in Brazil in the 1980s in the states of Amazonas and
Maranhão [5,6]. For this reason, an alternative therapeutic
regimen that combined sulphadoxine and pyrimethamine
(SP) was adopted as the first line treatment recommenda-
tion. However, resistance to SP was reported in northern
Tocantins State soon after its use was implemented
[7]. In 1982, resistance to SP was also described in
other Brazilian states, such as Rondônia, Pará, Ama-
zonas and Mato Grosso [8,9]. Subsequently, Boulos
et al. [10] reported 100% of therapeutic failure to SP
in 54 patients, and in the 1980s quinine in combin-
ation with tetracycline was introduced as first-line
treatment. Mefloquine was incorporated in the 1990s
as a new tool to treat resistant P. falciparum malaria,
but the emergence of chemoresistance [11] led to the
adoption of new strategies, such as artemisinin-based
combination therapy (ACT), as recommended by the
WHO in order to refrain the spread of resistance [12]. In
Brazil, since 2006 the first-line treatment recommendation
for non-complicated P. falciparum infections is the
use of artemether plus lumefantrine or artesunate plus
mefloquine combinations [13]. Nevertheless, decreased
sensitivity has already been reported in Southeast Asia
[14-16], Africa [17] and South America [18].
Resistance to anti-malarials is caused mainly by drug
pressure and selection of mutated parasites, and in
most cases single nucleotide polymorphisms (SNPs) in
the parasite genome are involved. Resistance to
chloroquine has been shown associated to SNPs in
the P. falciparum chloroquine resistant transporter
gene (pfcrt) on chromosome 7. Substitution of a lysine
by threonine at codon 76 was found in resistant para-
sites and, therefore, this mutation has been used as a
molecular marker for chloroquine resistance [19,20]
for both in vitro and clinical resistance assessment
[21]. Substitution of amino acids (T, N or I) in the
pfcrt mutant alters the electric charge of the membrane,
leading to chloroquine efflux from the digestive vacu-
ole [22,19].
The P. falciparum multidrug resistant gene (pfmdr1) on
chromosome 5 encodes the P-glycoprotein homologue-1
located in the parasite food vacuole and it is believed to be
associated to resistance to several anti-malarials [23]. Sub-
stitution of asparagine by tyrosine at codon 86 has been
shown associated with chloroquine and quinine resistance,
and increased sensitivity to mefloquine and artemisinin
derivatives [24]. Reed et al. [23] suggested that amino acid
change in position 1246 influences response to mefloquine,
quinine, halofantrine and artemisinin and modulates sensi-
tivity to chloroquine. Price et al. [25] reported an associ-
ation between increased pfmdr1 copy number and risk of
clinical failure with mefloquine when used in monotherapy
or in combination with artesunate. Parasites with increased
pfmdr1 copy number presented higher median IC50 values
of mefloquine, artemisinin derivatives, quinine and lume-
fantrine [25-27]. However, some authors did not find a
correlation between increased pfmdr1 copy numbers and
mefloquine resistance [28,29].
Pyrimethamine and sulphadoxine are antifolate drugs
that act by inhibiting the dihydrofolate reductase and dihy-
dropteroate synthase enzymes, respectively. Pyrimethamine
resistant P. falciparum presents a substitution of serine by
asparagine at codon 108 of the pfdhfr gene that encodes
the dihydrofolate reductase enzyme. Additionally, resistant
parasites may present N51I and C59R mutations in this
gene [30,31]. The A437G mutation in the P. falciparum
dihydropteroate synthase (pfdhps) gene confers resistance
to sulphadoxine. Additionally, other mutations at codons
436, 540, 581, and 613 are responsible for high level of
resistance [32]. The quintuple mutation (108N/51I/59R
and 437G/540E) in these two genes is considered a marker
of resistance to SP [33].
The continuous monitoring of molecular markers is a
very useful tool for malaria control, since it may guide
therapeutic policies. Several studies have assessed allele
frequencies in different time periods in Africa and Asia
[34,35]. In some scenarios, changes in chemotherapy
guidelines have led to a decline in the frequency of
mutant alleles after drug pressure was withdrawn [36]. In
this sense, it is important to investigate the genotypic
resistance profile of parasite populations submitted to
different drug pressures along time when different
therapeutic regimens were employed. This survey is of
particular importance for Brazilian isolates monitoring
since this country accounts for 52% of reported malaria
cases in the Americas [1]. This study aimed at describing
the occurrence of mutations in the pfcrt, pfmdr1, pfdhfr
and pfdhps genes over four decades, when the parasite
population was exposed to selective pressure of various
therapeutic approaches.
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Methods
Study setting and ethics
Samples were collected from patients admitted to health
services in São Paulo, SP and Santarém and Alenquer,
PA, with clinical malaria acquired in the Brazilian states of
Acre, Amapá, Amazonas, Mato Grosso, Pará, Rondônia
and Roraima. These states are located in the Amazon
basin, northern Brazil, where malaria transmission occurs
mainly during the dry season. Additionally, samples
from subjects infected in French Guiana, Guyana and
Suriname, countries bordering Brazil, were included
(Figure 1). Most of the latter cases were seen in Brazilian
miners who worked in bordering countries and returned
to Brazil for diagnosis and treatment. The number of
samples from each decade reflects epidemiological aspects
of malaria in Brazil, with fluctuations in the incidence of
the disease over the years, as influenced by the implemen-
tation of agricultural settlement projects and gold mining
activities [37]. Ethical approval for the study was obtained
from CONEP/Ministry of Health, Brazil (206/2012), and
all subjects gave informed consent for participation and
sample collection.
Study population and blood sample collection
Inclusion criteria required P. falciparum single infection
diagnosed by microscopy with any parasitaemia in subjects
of any age. Samples were collected from 1984 to 2011.
Samples obtained from 1984 to 2009 were stored in the
Malaria Laboratory/SUCEN/IMTSP biobank in liquid
Nitrogen. After thawing, 50 μL were plotted on Whatman
3® filter paper (Sigma-Aldrich®, St. Louis, MO, USA)
in duplicate. Samples from 2010 and 2011 were collected
Figure 1 Distribution of P. falciparum samples collected from 1984 to 2011 according to site of infection. In the detail, the number of
samples assayed for pfcrt, pfmdr1, pfdhfr and pfdhps.
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directly on filter paper by finger printing and stored
at room temperature until use. Although samples are
presented by decade of collection, the study population was
analysed according to the Brazilian national therapeutic
guidelines for malaria chemotherapy in use in the first
two decades (quinine plus tetracycline or mefloquine)
and in the last two decades (ACT), named periods 1
and 2, respectively.
Molecular identification of Plasmodium species
DNA from filter paper was extracted with Chelex® 100
(Bio-Rad™, Hercules, CA, USA) according to the protocol
by Plowe et al. [38] and stored at −20°C until use. To
confirm single infection by P. falciparum, nested PCR
targeting ssrRNA genes was performed following published
protocols [39].
Detection of pfcrt, pfmdr1, pfdhfr and pfdhps genotypic
polymorphisms
PCR followed by restriction fragment length polymorphism
analysis (RFLP) was performed to search for SNPs at
codons 76 of pfcrt; 86 and 1246 of pfmdr1; 51, 59 and 108
of pfdhfr, and 437 and 540 of pfdhps genes. For pfcrt 76 and
pfmdr1 86, fragments of 206 and 504 bp, respectively, were
amplified by PCR and submitted to enzyme digestion with
ApoI. For pfmdr1 1246, a 508 bp fragment was amplified
and digested with Eco321. Fragments of 206, 326 and
522 bp were amplified for codons 51, 59 and 108 of pfdhfr
and of 438 bp for both 437 and 540 codons of pfdhps gene.
Digestion was performed with TasI, PdmI, AluI for codons
51, 59 and 108 of pfdhfr and with HpyF10VI and
BsegI for codons 437 and 540 of pfdhps gene. DNA
samples from P. falciparum clones 3D7, Dd2 and Hb3
were used as controls. After RFLP, digestion products
were loaded onto ethidium bromide-stained 1× TBE 2%
agarose gels, and fragment sizes measured visually
based on a 100 bp DNA ladder and compared to control
fragments [40-42].
Determination of pfmdr1 copy number
Real time quantitative PCR was performed with iQ™
SYBR® Green Supermix (Bio Rad™, Hercules, CA, USA) to
determine pfmdr1 gene copy number. Reactions were
assayed in iCycler iQ Multicolor Real-Time PCR Detection
System (Bio Rad™, Hercules, CA, USA), with a 10-minute
incubation at 95°C, followed by 40 cycles with 15 seconds
95°C/1 minute 60°C. The melting curve was obtained
with one 10-minute cycle at 95°C. Samples were assayed in
triplicate, following a published protocol [43]. The 2-ΔΔCt
method was applied to estimate the pfmdr1 copy number,
using DNA of two calibrators with known copy numbers
(3D7, harbouring one copy and Dd2, four copies). The
housekeeping gene pfβactin1 was used as recommended in
order to normalize data.
Ex vivo anti-malarial sensitivity test
Twenty-two samples were assayed by ex vivo chemosensi-
tivity tests. Samples were collected in São Paulo, regardless
of site of malaria acquisition, during the two first decades,
period when quinine plus tetracycline and mefloquine were
employed. Samples from patients who received any
anti-malarial drug in the previous 30 days before
sample collection were excluded. Each sample was
assayed with chloroquine, quinine and mefloquine to
determine Minimal Inhibitory Concentrations (MIC).
Isolates were exposed to different drug concentrations in
serial dilutions for 72 hours in pre-dosed microplates, as
follows: 10, 20, 40, 57, 80, 160 and 320 nM chloroquine,
40, 80, 160, 320, 640, 1280 and 2560 nM quinine and 5,
10, 20, 40, 57, 80 and 160 nM mefloquine. Infected blood
was added to RPMI complete medium in 10% hematocrit,
in 5% CO2, 5% O2 and 90% N2 atmosphere in a 37°C
incubator. Drug response was assessed counting the
number of schizonts/200 parasites in Giemsa-stained
thick blood films, using microcultures carried out in the
same conditions but without exposure to anti-malarial
drugs as controls. In addition, reference P. falciparum Palo
Alto and K1 isolates were used as controls for chloroquine-
sensitive and -resistant strains, respectively [44].
In vivo treatment
Clinical data related to treatment were obtained from
medical records both at the time of diagnosis and during
follow-up. All patients were treated following Brazilian
national guidelines for malaria chemotherapy or approved
research therapeutic protocols (artemether or artesunate
in monotherapy). Recrudescent parasitaemia after use of
artemisinin derivatives in monotherapy were treated
according to Brazilian guidelines [13,45]. Monitoring
of parasitaemia was carried out on days 3, 7, 14, 28 and 35
after treatment was started. Therapeutic regimens are
presented in Figure 2.
Statistical analysis
The Fisher’s Exact Test (GraphPad) was applied in search
of associations between in vivo or ex vivo phenotypic
responses to quinine, mefloquine and artemisinin
derivatives and the presence of mutations at each
codon (pfmdr1 86 and 1246). The same test was used to
check for association between phenotypic response and
pfmdr1 copy number. P values <0.05 were considered
statistically significant.
Results
Origin of samples
A total of 96 samples from patients infected in Brazil
were assessed. Twenty-six samples were collected in the
1980s, 38 in the 1990s, four in the 2000s and 28 in the
2010s. Additionally, nine samples collected from patients
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infected in the 2010s in countries bordering Brazil
(French Guiana, Guyana and Suriname) were evaluated.
pfcrt and pfmdr1
All Brazilian samples presented the pfcrt 76T mutant in
periods 1 and 2. As for pfmdr1, the 86Y mutant was
identified through in the 1990s and 2010s in different
frequencies, when all but one mutant isolate harbour-
ing the genotype 86Y were obtained from patients
diagnosed in Pará State (Table 1). This mutant was
also observed in 43% of samples collected in Pará
State from patients infected in Guyana in the 2010s.
All Brazilian samples as well as isolates from bordering
countries presented the 1246Y mutant genotype in the
two evaluated periods (Table 1). Assessment of pfmdr1
copy numbers from Brazilian isolates are summarized
in Table 1.
pfdhfr and pfdhps
Mutations in positions 51, 59 and 108 of the pfdhfr gene
are described in Table 1. Mutants at position 51 are less
frequently described in period 2 and at position 59
emerged as single or mixed infections. All isolates
presented the mutation in position 108 in all periods.
Considering the samples from countries bordering
Brazil, 8/9 presented 51I, 1/9 51 N + I and 1/9 59 C + R;
all samples presented 108 N genotype. With respect to
pfdhps gene, samples from both periods presented the
437G mutant genotype. At position 540, a slight decrease
in the frequency of the mutant was observed (Table 1).
Regarding the samples from countries bordering Brazil, all
samples presented 437G and 540E.
Multiple mutants
As for multiple mutations in positions 51, 59 and 108 of
the pfdhfr gene and 437 and 540 of pfdhps, 95.3% and
4.7% of Brazilian samples from period 1 presented quadru-
ple (ICNGE) and triple mutation (ICNGK), respectively. In
period 2, it was detected quintuple mutation (IRNGE) in
12.9%, quadruple ICNGE in 61.3% and IRNGK in 9.7%.
Triple mutation (ICNGK) was detected in 16.1%, as shown
in Figure 3.
Figure 2 Therapeutic schemes in patients treated from 1984 to 2011 based on Brazilian guidelines or approved therapeutic protocols.
Table 1 Genotyping of pfcrt, pfmdr1, pfdhfr and pfdhps in P. falciparum from Brazil, according to two distinct
therapeutic regimen periods
Period pfcrt pfmdr1 pfdhfr pfdhps
76 86 1246 Copy number 51 59 108 437 540
T (%) Y (%) Y (%) 1 (%) >1 (%) I (%) N + I (%) R (%) C + R (%) N (%) G (%) E (%) K + E (%)
1 100 1.5 100 62.7 37.3 100 0 0 0 100 100 93.7 1.5
2 100 25 100 58 42 81.2 18.7 6.4 16.1 100 100 75 0
Inoue et al. Malaria Journal 2014, 13:372 Page 5 of 10
http://www.malariajournal.com/content/13/1/372
Clinical response to chemotherapy
Thirty-four patients who completed clinical follow-up
for at least 28 days after being started on chemotherapy
were evaluated. Out of these 27 had received anti-malarials
following Brazilian national guidelines at time of diagnosis,
six patients had been treated with artemisinin derivatives
in monotherapy as subjects enrolled for a clinical research
protocol, and one individual was treated with artesunate
plus quinine hydrochloride due to very high parasitaemia
at time of diagnosis. Patients were defined as harbouring
sensitive or resistant parasites in case they exhibited
absence or presence, respectively, of Plasmodium on day
28 after being started on chemotherapy. Clinical response
to treatment according to therapeutic regimens is shown
in Figure 4.
pfcrt genotypic polymorphism versus ex vivo response to
chloroquine
Twenty-one samples were assayed for chloroquine
sensitivity using an ex vivo test. All isolates showed a
resistant phenotype with MIC ≥ 80 nM. In addition,
all samples showed the pfcrt 76T mutant genotype
when assayed by RFLP.
pfmdr1 genotypic polymorphism versus ex vivo and
in vivo responses
Among the isolates resistant to chloroquine, one was
resistant to quinine but not to mefloquine, and six were
resistant to mefloquine but not to quinine. Nineteen
samples were tested ex vivo for quinine sensitivity, 5.2% of
which revealed a resistant phenotype, with MIC > 2560 nM.
On molecular analysis, this sample presented a wild type
genotype for codon 86 and a 1246Y mutant. All sensitive
samples presented the same genotypic profile. Ex vivo tests
for mefloquine were performed in 22 samples and in 27.3%
of them yielded MIC > 160 nM. The wild type genotype for
codon 86 and the mutant 1246Y were seen in all resistant
samples. One sensitive sample showed the mutant
86Y. Regarding copy numbers, out of six mefloquine-
resistant isolates, four presented two copies of pfmdr1
and two, one copy only. Five out of 13 mefloquine-sensitive
isolates showed two or more gene copies and eight
out of 13, one copy only. Three isolates assayed for
mefloquine showed no amplification for pfmdr1 copy
number assessment.
As far as the in vivo response to chemotherapy is
concerned, all patients presented a clinical recrudescence
after having received quinine in monotherapy, 20% after
treatment with mefloquine and 66.6% of those who were
given artemisinin derivatives in monotherapy. All these
samples harboured the N86 wild genotype and the 1246Y
mutant as well as those from patients who did not present
recrudescent malaria.
Statistical analysis
The Fisher’s Exact Test showed no association between
the in vivo clinical response to quinine and the occur-
rence of pfmdr1 mutations in codons 86 and 1246
(p = 1.000), neither between clinical response after
chemotherapy and the pfmdr1 copy number (p = 1.000).
In addition, no association was found between the in vivo
response to mefloquine and mutations in codon 86
(p = 1.000), 1246 (p = 1.000) or with pfmdr1 copy number
(p = 1.000). Likewise, mutations in codons 86 and 1246 or
variation in gene copy number were not shown associated
with in vivo clinical response to artemisinin deriva-
tives (p = 1.000). No statistically significant association
was seen between the ex vivo response to quinine and
mefloquine and pfmdr1 mutations in codons 86 and
1246 (p = 1.000), neither between copy number and
ex vivo clinical response to mefloquine (p = 0.3498) or
quinine (p = 1.000).
Figure 3 Distribution of quintuple (IRNGE), quadruple (ICNGE and IRNGK) and triple (ICNGK) mutations in pfdhfr and pfdhps genes in
Brazilian isolates.
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Discussion
This is the first study to assess P. falciparum genotypic
polymorphisms related to chemoresistance in Brazilian
samples collected over a 27-year period when different
national therapeutic policies were successively in place.
Analysis of pfcrt gene showed that all samples harboured
the 76T mutation, strongly associated to chloroquine
resistance, throughout the evaluated periods, even though
this 4-aminoquinoline was replaced by quinine in
monotherapy or associated to tetracycline in Brazilian
national guidelines for malaria chemotherapy in the
mid-1980s [46,47]. Assessment of pfcrt mutations is
relevant to monitor molecular changes that could
have led to reversal of chloroquine resistance after
drug withdrawal, as seen in Malawi. In this African
country, absence of drug pressure yielded restauration of
chloroquine-sensitive genotypes in the parasite population
[36]. A similar phenomenon occurred in Kenya with
substantial reversal to the K76 genotype [48]. In
Africa, P. falciparum accounts for most human malaria
infections and chloroquine withdrawal after introduction
of ACT removed selective drug pressure on the parasite.
Such reversal, however, is not expected to take place in
South America, a region characterized by high prevalence
of P. vivax infections, which require uninterrupted use of
chloroquine. In such a scenario, fixation of the mutant
genotype is supported. In addition, it is important to
consider that chloroquine is still widely used in this
region for the treatment of rheumatic diseases including
systemic lupus erythematosus, contributing to an increased
drug pressure in the P. falciparum genome [49]. The results
of pfcrt genotyping with samples from countries bordering
Brazil are in agreement with studies conducted in French
Guiana [50] and Suriname [51], where therapeutic policies
have been similar to those adopted in Brazil. Moreover, the
molecular results are concordant with results of the ex vivo
assays that revealed full resistance to chloroquine with all
tested isolates.
The pfmdr1 gene has been previously reported to be
involved with increased resistance to chloroquine and
quinine, and with increased sensitivity to mefloquine
and artemisinins [24] or, in contrast, with increased
sensitivity to quinine [52]. In this study, the N86 wild
type was detected in almost all samples from periods 1 and
2, in agreement with earlier reports from Suriname [51]
and other South American countries [53,54]. Considering
that in period 1 Brazilian national chemotherapy guidelines
recommended three different therapeutic approaches, i.e.,
use of chloroquine, quinine and mefloquine, it is possible
to conclude that drug pressure was not able to select a
mutant genotype. This hypothesis is corroborated by the
lack of association between results obtained in in vivo and
ex vivo assays. However, an aspect to be highlighted is the
emergence of the 86Y mutant in the last decade of period
2 in 25% of Brazilian samples and in 43% of isolates
from Guyana. Even though increased sensitivity to
artemether-lumefantrine has been linked to the pfmdr1
N86 wild type in Africa [55], Bustamante et al. [56] found
association between decreased sensitivity to artemether
and the occurrence of the 86Y mutant using in vitro tests.
ACT was introduced in Brazil and in Guyana in 2006. In
Guyana, P. falciparum is the most prevalent species and a
drug efficacy study showed 70.1% of patients positive at
day 3 after artemether-lumefantrine treatment [57]. In
gold mining and logging areas in Guyana, symptoms
related to malaria are first taken care of at informal health
facilities, where a wide range of anti-malarials, including
artemisinin derivatives is available [58,59]. Taking the high
flow of miners between Brazil and neighbouring countries
into account, it is possible to hypothesize that the
emergence of pfmdr1 86Y could be related to the
indiscriminate use of ACT from the mid-2000s in that
Figure 4 Treatment response according to therapeutic regimens in patients with at least 28-day follow-up.
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region. Although no association was found between
in vivo failure to artemisinin and the 86Y polymorphism,
selection for this mutant requires continuous monitoring of
P. falciparum in this region. Another relevant issue to be
discussed is the fact that all samples harboured the 1246Y
genotype throughout the evaluated periods. These results
are concordant with observations by other investigators
from South America, in which analysis of this codon
showed only mutant parasites [51,54]. In conclusion,
despite several changes in recommendations for malaria
chemotherapy along the two periods, no genotypic selec-
tion occurred at this codon, as postulated in a study with
samples from Venezuela [54].
Analysis of the pfdhfr gene showed the emergence of
the 59R mutant in the more recent period. Additionally
a high frequency of mutants at codons 51 and 108 was
detected in all assessed periods. As for the pfdhps gene,
a high frequency of mutants at codons 437 and 540 was
observed. In Peru, removal of SP from chemotherapy
recommendations was followed by reduction from 47% to
16.9% in the prevalence of the pfdhfr mutant haplotype, as
well as in pfdhps with 83.8% of isolates exhibiting the
wild type allele [60]. In contrast, a study conducted
in Venezuela eight years after the withdrawal of SP
showed resistance-associated mutations fixed in the
parasite population, suggesting that in low transmission
areas, fixation of resistant parasites is stable even after
removal of drug pressure [61]. This scenario seems to
occur in Brazil, where withdrawal of SP occurred in the
1980s. Although the emergence of codon 51 wild type
allele was observed, the 108N mutant is still present in the
parasite population. When compared to a previous study
carried out in 1991 with P. falciparum samples from the
Amazon region, results of the present study show an
increase of 90% to 100% in the prevalence of the pfdhfr
108N mutation [62]. Such evidence discourages recom-
mending the use of artemisinin derivatives combined with
SP in Brazil. In fact, the use of artesunate plus SP in
Mozambique led to a dramatic increase of mutants in a
short period after the establishment of this policy [63].
Finally, all samples presented the pfcrt 76T genotype
and resistance to chloroquine in those assayed ex vivo. A
comparison of these results with an in vivo response was
however unfeasible, as chloroquine has not been used in
Brazil to treat falciparum malaria since the beginning
of the first period. Nevertheless, the use of pfcrt as a
molecular marker for chloroquine resistance is strengthened
by the present findings. Although amplification of pfmdr1
has been previously associated with reduced susceptibility
to mefloquine [25] and lumefantrine [64] and susceptibility
to quinine [27], statistical analysis in this study did
not show association between mutations in pfmdr1
codons 86 and 1246, or between pfmdr1 copy number
variation with in vivo or ex vivo responses to quinine
and mefloquine. The same result was observed with the
in vivo response to artemisinin derivatives, in a group of
patients treated outside the transmission area, without any
possibility of reinfection, and followed for at least
28 days. Likewise no significant differences between
ex vivo response to dihydroartemisinin, quinine and
mefloquine were observed regarding pfmdr1 86 and
1246 mutations, in an African study [65]. The role of
pfmdr1 in anti-malarial resistance remains thus con-
troversial, since various epidemiological variables may
differently modulate selection to which parasite populations
are submitted to [66]. Furthermore, the Kelch13 gene,
located on P. falciparum chromosome 13 [67] and the
pfAP2μ [68] is believed to be involved in decreased
response to artemisinin derivatives.
Limitations of this study include small sample sizes for
in vivo and ex vivo analyses, as well the fact that the
number of samples was different in periods 1 and 2.
Nevertheless, the present report has been able to provide an
idea of the extent in which different malaria chemothera-
peutic recommendations used in Brazil have impacted P.
falciparum genotypic profile in the country.
Conclusions
The pfcrt 76T mutant was demonstrated in all analysed
isolates and full chemoresistance to chloroquine was
shown in ex vivo response assessment. The results are
also conclusive with respect to the high prevalence of
pfdhfr and pfdhps mutants, indicating that SP should not
be combined with artemisinin derivatives in Brazil.
These findings reinforce the multidrug resistant pattern
of Brazilian P. falciparum isolates. It was confirmed the
fixation of 76T pfcrt, in spite of the fact that chloroquine
was withdrawn from chemotherapy in the beginning of
the first period considered in this study. Fixation of the
mutant is believed to be due to continuous use of
chloroquine for P. vivax infections, the most prevalent
human malaria in Brazil. Likewise, mutations in pfdhfr
and pfdhps genes showed no remarkable changes even
after substitution of SP by different treatment regimens.
Pfmdr1 presented single or multiple copies regardless of
treatment policy. Analysis of SNPs in pfmdr1 showed
maintenance of the molecular profile except for emergence
of 86Y in period 2, when ACT was adopted. The lack of
association between phenotypic response to quinine,
mefloquine and artemisinin derivatives with SNPs in the
pfmdr1 gene highlight the need for more informative tools,
such as genomic wide scan, to identify polymorphisms
that could be used as molecular markers of anti-malarial
chemoresistance in Brazilian P. falciparum isolates.
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